Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Several of the company's key product candidates, including UCART19, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing its other product candidates as part of the lymphodepletion regimen.

Altisource Portfolio Solutions is a marketplace and transaction solutions provider for the real estate, mortgage and consumer debt industries. Co. has three reportable segments: mortgage services, which provides asset management services, origination services, insurance services, property valuation services, and default management services; financial services, which provides collection services primarily to debt originators and servicers and customer relationship management services primarily to the utility, insurance and hotel industries; and technology services, which provides software and data analytics solutions and information technology infrastructure management services.

Appian provides low-code automation platform that accelerates the creation of business applications, enabling its customers to automate their business. The company's platform automates the creation of forms, data flows, records, reports and other software elements that would otherwise need to be manually coded. The company'snSelf-Assembling Interface Layer technology ensures that applications developed on its platform can be deployed across a range of mobile and desktop devices, including desktop web browsers, tablets and mobile phones. The company's platform can be deployed in the cloud or on-premises, with organizations able to access the same functionality and data sources in various cases.

BridgeBio operates as a bio technology company. The company focuses on development of medicines for genetic diseases. The company serves patients worldwide.

Corvus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. The company develops small molecules that are designed to selectively inhibit the binding of immunosuppressive adenosine to either A2A receptors or to A2B receptors. The company's initial product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine. The company's second clinical product candidate, CPI-006, is an anti-CD73 monoclonal antibody that is designed to both inhibit the production of adenosine and stimulate various immune cells. The company's third clinical product candidate, CPI-818, is a selective, covalent inhibitor of ITK.

Crocs is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear and accessories for men, women, and children. The company provides a variety of footwear products including sandals, flips and slides, which the company collectively refer to as sandals, shoes, and boots. The majority of shoes within the company's collection contains Croslite? material. The company's wholesale channel includes domestic and international multi-brand retailers, e-tailers, and distributors; the company's retail channel consists of company-operated stores; and the company's e-commerce channel includes company-operated e-commerce sites and third-party marketplaces.

DocuSign provides e-signature solution as the main part of its cloud software suite for automating the agreement process. The company calls its suite the DocuSign Agreement Cloud. The DocuSign Agreement Cloud is designed to allow companies of various sizes and across various industries to make agreement, approval process, or transaction digital, from practically any device, from almost anywhere in the world.

Myers Industries manufactures a range of polymer products for industrial, agricultural, automotive, commercial and consumer markets. The company has two business segments: Material Handling and Distribution. The Material Handling segment manufactures polymer packaging containers, storage and safety products, and specialty molded parts. The brands within this segment include Buckhorn?, Akro-Mils?, Jamco Products, Ameri-Kart?, and Scepter. The company's Distribution segment includes the Myers Tire Supply?, Myers Tire Supply International? and Patch Rubber Company? brands. Within the Distribution Segment Co. sources and manufactures products for the tire, wheel and undervehicle service industry.

OncoCyte is focused on developing non-invasive molecular diagnostic tests for cancer diagnosis. The company is developing DetermaVu?, a non-invasive molecular lung cancer confirmatory diagnostic that can be administered to patients as a blood test. DetermaVu? utilizes proprietary sets of gene expression markers to help confirm whether lung nodules detected via Low Dose Computed Tomography scans, x-rays or other imaging are likely to be benign or malignant. DetermaVu? is based on the company's Immune System Interrogation approach that checks the body's immune system response to a specific disease by measuring differential RNA expression in patients with the disease versus patients without the disease.

Republic First Bancorp is a bank holding company. Through its subsidiary, Republic First Bank, the company provides a variety of credit and depository banking services. The company provides a range of banking products and services, including consumer and commercial deposit accounts, checking accounts, interest-bearing demand accounts, money market accounts, certificates of deposit, savings accounts, sweep accounts, lockbox services and individual retirement accounts and other banking services, secured and unsecured commercial loans, real estate loans, construction and land development loans, automobile loans, home improvement loans, mortgages, home equity and overdraft lines of credit, and other products.

Stewart Information Services, through its subsidiaries, is primarily engaged in the business of providing title insurance and real estate transaction related services. The company is a global real estate services company, providing products and services through its directly owned policy-issuing offices, network of independent agencies and other businesses within the company The company has two segments: title insurance and related services, which include the functions of searching, examining, closing and insuring the condition of the title to real property; and ancillary services and corporate, which provides search and valuation services to the mortgage industry through Stewart Lender Services, Inc.